GTG appointments expected to boost test service
22 April, 2003 by Melissa TrudingerMelbourne biotechnology company Genetic Technologies (ASX: GTG) has appointed two Australian scientists to assist it with the set up of its new cancer susceptibility genetic testing service.
BresaGen soars on Parkinson's results
14 April, 2003 by Melissa TrudingerAustralian stem cell company BresaGen has demonstrated functional recovery from the effects of Parkinson's disease in a rat model treated with human dopaminergic neurons derived from human embryonic stem cells.
Singapore: report slams non-ethical research practices, director fired
09 April, 2003 by Kate WebsterSingapore's efforts to become a global hub for the biomedical sciences faced its first major hurdle last week with the sacking of world-renowned British neurologist, Dr Simon Shorvon, from his post as the director of the National Neuroscience Institute.
Study backs theory that TB jab could guard against asthma
07 April, 2003 by Graeme O'NeillA Sydney epidemiological study has given further weight to a theory that exposure to non-viral respiratory infections in childhood may protect against asthma later in life.
The research road to doctorate
27 March, 2003 by Graeme O'NeillWorking hard for low pay, but Graeme O'Neill reports that the pursuit of a PhD could be the most rewarding time in a scientist's life.
US firm claims Vision Bio infringed patents
26 March, 2003 by Melissa TrudingerA legal battle has erupted over Vision BioSystems' new cancer detection instruments, with US company Ventana Medical Systems filing claims alleging patent infringement in a US court last week.
Prana teams with NSV, Schering
24 March, 2003 by Melissa TrudingerMelbourne company Prana Biotechnology has announced an agreement with Neurosciences Victoria and German pharma Schering worth up to $AUD7.5 million over the next three to five years.
CSIRO fields cancer diagnosis tools
20 March, 2003 by Jeremy TorrCSIRO Bioinformatics, a spin-off company from CSIRO Mathematical and Information Sciences, has developed new statistical methods it says could lead to improved diagnosis and treatment of cancers.
Starpharma gel wards off retrovirus infection
19 March, 2003 by Graeme O'NeillMelbourne nano-biotech company Starpharma Pooled Development (ASX:SPL) announced today that tests in the US have shown that its lead compound, a intravaginal gel developed to protect against sexually transmitted diseases, is completely effective in warding off an HIV-like retrovirus infection in macaque monkeys.
World on alert as unidentified pneumonia strikes
17 March, 2003 by Graeme O'NeillInternational health authorities have gone on high alert as more reports emerge from south-east Asian countries of deaths and illness caused by an unidentified, potentially lethal pneumonia-like infection dubbed Hong Kong severe acute respiratory syndrome.
Prana chief wins award
17 March, 2003 by Graeme O'NeillThe American Academy of Neurology has given its 2003 Potamkin Award for research into Alzheimer's disease to Dr Ashley Bush, co-founder of Melbourne biotechnology company Prana Biotechnology (ASX: PBT).
Melbourne scores $10 million Diabetes Vaccine Centre
14 March, 2003 by Jeremy TorrMelbourne has been chosen as the site for the world's first Diabetes Vaccine Development Centre, a joint initiative of the National Health and Medical Research Council and the Juvenile Diabetes Research Foundation International.
Domantis signs deal with ImClone
11 March, 2003 by Graeme O'NeillUS anti-cancer therapeutics company ImClone Systems has signed an agreement with UK antibody engineering company Domantis, to use Domantis' proprietary domain-antibody technology to develop new therapeutics.
Remicade royalty refusal beggars analysis
04 March, 2003 by Graeme O'NeillUS biomedical company Centocor continues to puzzle analysts and investors alike with its refusal to pay royalties on its market-leading rheumatoid arthritis therapy Remicade to small Sydney biotechnology company Peptech.
CK Life, Swinburne team to trial ancient remedy as potential AIDS vaccine
03 March, 2003 by David BinningCK Life Sciences, the biotech child of Asian business tycoon Li Ka Shing, will this month start an Australian trial of an AIDS vaccine drawn from ancient Chinese herbal remedies after inking a $600,000 deal with the Swinburne University Graduate School of Integrative Medicine.
